Merck and Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, have entered an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 trial in China in adults with elevated Lp(a) at high risk for cardiovascular events. Under the agreement, Merck has exclusive rights to develop, manufacture, and commercialize HRS-5...